Search Results for “diabetes” – Page 47 – media

Blockchain medical device set to improve the delivery for babies born by C-section

NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.
- Source: Open Access Government
- 662
- March 19, 2018
blockchain digital health Researches
mHealth Tools, AI Combine to Avert Serious Diabetic Health Issues

mHealth tools embedded with AI technology are helping doctors and those living with diabetes detect hyperglycemia and hypoglycemia up to an hour ahead of time, averting serious and potentially fatal health issues.
- Source: drugdu
- 1,246
- March 19, 2018
AI Company Insight digital health mHealth
Fitbit unveils new tracker for kids, new smartwatch for adults

Come this spring adults won’t be the only ones with their own line of Fitbit trackers. The company recently announced a new set of products including the Fitbit Ace, which is a tracker designed for children 8 years old and up, as well a much anticipated new smartwatch, the Fitbit Versa.
- Source: MobiHealthNews
- 588
- March 14, 2018
Company Insight digital health Fitbit wearables
GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
- Source: us.gsk
- 882
- March 12, 2018
asthma EC GSK Relvar Ellipta
Bay Area’s Rani Therapeutics Lands $53M as Company Moves to Clinical Trials

Rani Therapeutics scored $53 million in financing to take its oral pill designed to replace injectable drug delivery for chronic disease treatment into clinical trials.
- Source: Biospace
- 474
- February 28, 2018
chronic diseases Company Insight oral pill
Implanted continuous glucose sensor proven safe

Senseonics Holdings Inc has announced that people with diabetes using the Eversense® brand Continuous Glucose Monitoring Systems, in EMEA markets now have the option to invite others to remotely view their real-time glucose readings and alerts from anywhere.
- Source: globalbiotechinsights
- 714
- February 28, 2018
diabetes medical device mHealth New Approvals
UK’s NHS Aims to Build a Library of Reliable Mobile Health Apps.

The UK's National Health Service is putting out the call for more mobile health apps for its NHS Apps Library, and has chosen an agency to certify those apps. The library now features 46 mHealth apps - only one of which has passed muster.
- Source: mHealth Intelligence
- 651
- February 27, 2018
Company Insight digital health mHealth
FDA Orders Recall of Drug Dosage mHealth App for Diabetic Patients

The FDA has ordered the recall of a mHealth app that helps people with diabetes determine how much insulin they should inject. The issue points to the continuing challenge of verifying the accuracy of digital health devices and drug dosage apps.
- Source: mHealth Intelligence
- 778
- February 26, 2018
diabetes FDA mHealth Policies
Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
- Source: Merck
- 518
- February 19, 2018
Company Insight Merck
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The updated label includes Cosentyx data in moderate to severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.1-3 The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.6
- Source: pharma.us.novartis
- 552
- February 13, 2018
Cosentyx® FDA New Approvals Scalp psoriasis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.